Endry H T Lim

ORCID

Publication Activity (10 Years)

Years Active: 2022-2023
Publications (10 Years): 7

Top Venues

The European respiratory journal

Expert review of anti-infective therapy

Transfusion

Clinical and translational science

This page only lists publications with an associated author ORCID identifier.

Publications

Endry H T Lim, Alexander P J Vlaar, Sanne de Bruin, Matthijs C Brouwer, Diederik van de Beek
C5 inhibitors are not C5a inhibitors. Expert review of anti-infective therapy (2023)
Erik Asmus, Weronika Karle, Markus C Brack, Corey Wittig, Felix Behrens, Leander Reinshagen, Moritz Pfeiffer, Sabrina Schulz, Bertina Mandzimba-Maloko, Lasti Erfinanda, Paul L Perret, Laura Michalick, Patrick J Smeele, Endry H T Lim, Charissa E van den Brom, Alexander B A Vonk, Toralf Kaiser, Norbert Suttorp, Stefan Hippenstiel, Leif E Sander, Florian Kurth, Ursula Rauch, Ulf Landmesser, Arash Haghikia, Robert Preissner, Harm J Bogaard, Martin Witzenrath, Wolfgang M Kuebler, Robert Szulcek, Szandor Simmons
Cystic fibrosis transmembrane conductance regulator modulators attenuate platelet activation and aggregation in blood of healthy donors and COVID-19 patients. The European respiratory journal 61 (3) (2023)
Erik Asmus, Weronika Karle, Markus C Brack, Corey Wittig, Felix Behrens, Leander Reinshagen, Moritz Pfeiffer, Sabrina Schulz, Bertina Mandzimba-Maloko, Lasti Erfinanda, Paul L Perret, Laura Michalick, Patrick J Smeele, Endry H T Lim, Charissa E van den Brom, Alexander B A Vonk, Toralf Kaiser, Norbert Suttorp, Stefan Hippenstiel, Leif E Sander, Florian Kurth, Ursula Rauch, Ulf Landmesser, Arash Haghikia, Robert Preissner, Harm J Bogaard, Martin Witzenrath, Wolfgang M Kuebler, Robert Szulcek, Szandor Simmons
Cystic fibrosis transmembrane conductance regulator modulators attenuate platelet activation and aggregation in blood of healthy donors and COVID-19 patients. The European respiratory journal 61 (3) (2023)
Endry H T Lim, Alexander P J Vlaar, Sanne de Bruin, Matthijs C Brouwer, Diederik van de Beek
Letter in response to 'The efficacy and safety of complement C5a inhibitors for patients with severe COVID-19: a systematic review and meta-analysis' by Tsai et al. Expert review of anti-infective therapy (2023)
Endry H T Lim, Alexander P J Vlaar, Sanne de Bruin, Simon Rückinger, Claus Thielert, Maria Habel, Renfeng Guo, Bruce P Burnett, James Dickinson, Matthijs C Brouwer, Niels C Riedemann, Diederik van de Beek, null null
Pharmacokinetic analysis of vilobelimab, anaphylatoxin C5a and antidrug antibodies in PANAMO: a phase 3 study in critically ill, invasively mechanically ventilated COVID-19 patients. Intensive care medicine experimental 11 (1) (2023)
Frank E H P van Baarle, Sanne de Bruin, Esther B Bulle, Niels van Mourik, Endry H T Lim, Anita M Tuip-de Boer, Annabel Bongers, Marit B de Wissel, Robin van Bruggen, Dirk de Korte, Christie Vermeulen, Khik Wie Tan, René E Jonkers, Peter I Bonta, René Lutter, Tamara Dekker, Barbara S Dierdorp, Anna L Peters, Bart J Biemond, Alexander P J Vlaar
Aged versus fresh autologous platelet transfusion in a two-hit healthy volunteer model of transfusion-related acute lung injury. Transfusion 62 (12) (2022)
Alexander P. J. Vlaar, Endry H T Lim, Sanne de Bruin, Simon Rückinger, Korinna Pilz, Matthijs C Brouwer, Ren-Feng Guo, Leo M A Heunks, Matthias H Busch, Pieter van Paassen, Niels C Riedemann, Diederik van de Beek
The anti-C5a antibody vilobelimab efficiently inhibits C5a in patients with severe COVID-19. Clinical and translational science 15 (4) (2022)

Endry H T Lim.css-eqlu8i{font-size:small;padding-left:4px;}

Publication Activity (10 Years)

Top Topics

Top Venues

Endry H T Lim